Greenwich LifeSciences (NASDAQ:GLSI) is a clinical‐stage biopharmaceutical company focused on the development of innovative therapies to address obesity and metabolic disorders. Since its inception in 2017, the company has dedicated its research efforts to novel mechanisms of action that improve energy balance and metabolic health. Headquartered in Greenwich, Connecticut, Greenwich LifeSciences operates research and development facilities in the United States and collaborates with leading academic institutions to advance its pipeline candidates through preclinical and clinical stages.
The company’s primary product candidates are designed to enhance leptin sensitivity and optimize key hormonal pathways involved in appetite regulation and energy expenditure. By targeting molecular signals that influence weight management, Greenwich LifeSciences aims to overcome the limitations of existing treatments and deliver therapies with improved safety and efficacy profiles. The pipeline includes both monotherapy and combination approaches, with a strategic emphasis on unmet needs in obesity, nonalcoholic fatty liver disease (NAFLD), and related cardiometabolic conditions.
Greenwich LifeSciences serves a global patient population, with clinical trial sites across North America and Europe. The company leverages partnerships with contract research organizations and international distributors to facilitate study enrollment and prepare for eventual commercial launch. In addition to obesity, its R&D programs explore applications in Type 2 diabetes and inflammatory liver diseases, reflecting a broader commitment to metabolic health. Through strategic alliances, Greenwich LifeSciences is positioned to accelerate regulatory filings and expand its geographic reach upon successful trial outcomes.
Under the leadership of Chief Executive Officer Keith F. Pierson, Greenwich LifeSciences is supported by a board and management team with decades of experience in biotechnology and pharmaceutical development. The executive team includes veterans in clinical development, regulatory affairs, and commercial strategy, all united by the goal of bringing first‐in‐class therapies to market. Guided by a scientific advisory board of renowned endocrinologists and metabolic disease experts, the company continues to advance its mission of delivering transformative treatments for patients struggling with obesity and its complications.
